Long-term calcineurin inhibitor "holiday" using daclizumab in a heart transplant patient with acute renal dysfunction [5]

Journal of Heart and Lung Transplantation

Volumn 24, Issue 8, 2005, Pages 1126-1128

  Potter, B ^a   Giannetti, N ^a   Cecere, R ^a   Cantarovich, M ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; DACLIZUMAB; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; THYMOCYTE ANTIBODY;

ACUTE KIDNEY FAILURE; ADULT; ANAMNESIS; BONE MARROW TOXICITY; CARDIAC GRAFT REJECTION; CARDIOMYOPATHY; CASE REPORT; CLINICAL FEATURE; GASTROINTESTINAL TOXICITY; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; MALE; PERIPHERAL EDEMA; PLASMAPHERESIS; PRIORITY JOURNAL; RASH; SIDE EFFECT;

ANTIBODIES, MONOCLONAL; CALCINEURIN; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HEART TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, ACUTE; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RENAL DIALYSIS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 23744511695     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2004.10.002     Document Type: Letter

References (5)

1. M. Cantarovich, E. Elstein, B. de Varennes, J.S. Barkun Clinical benefit of neoral dose monitoring with cyclosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients Transplantation 68 1999 1839 1842
2. M.E. Billingham, N.R.B. Cary, M.E. Hammond A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection Heart Rejection Study Group J Heart Transplant 9 1990 587 593
3. M. Cantarovich, P. Metrakos, N. Giannetti, R. Cecere, J. Barkun, J. Tchervenkov Anti-CD25 monoclonal antibody coverage allows for calcineurin inhibitor "holiday" in solid organ transplant patients with acute renal dysfunction Transplantation 73 2002 1169 1172
4. F. Vincenti, B. Nashan, S. Light Double and Triple Therapy Study Groups Daclizumab outcome of phase III trials and mechanism of action Transplant Proc 30 1998 2155 2158
5. F. Vincenti, D. Pace, J. Birnbaum, M. Lantz Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantation Am J Transplant 3 2003 50 52